Does Aspirin Reduce Vascepa's Efficacy?
Concurrent low-dose aspirin use (typically 81 mg daily) does not reduce Vascepa's (icosapent ethyl) efficacy in reducing cardiovascular events among heart patients. Clinical trials show Vascepa lowers major adverse cardiovascular events (MACE) by 25% overall, with consistent benefits in patients on aspirin—88% of REDUCE-IT trial participants used aspirin, and subgroup analysis confirmed no interaction or diminished effect.[1][2]
What Showed This in Key Trials?
The pivotal REDUCE-IT trial (2018) tested Vascepa 4g/day versus placebo in 8,179 statin-treated patients with high triglycerides and cardiovascular risk. Aspirin was common (88% in both arms), and multivariate analysis found no evidence of reduced efficacy; hazard ratios for MACE remained favorable (HR 0.75 overall, similar in aspirin users).[1][3] A post-hoc analysis reinforced this, with event reductions holding across antiplatelet subgroups.[2]
Why Might Patients Worry About This Interaction?
Concerns stem from older fish oil studies (e.g., meta-analyses of non-purified EPA/DHA) suggesting high-dose omega-3s could increase bleeding risk or blunt antiplatelet effects with aspirin/clopidogrel. Vascepa, however, is pure EPA ethyl ester, avoiding DHA-related issues. No such pharmacokinetic interaction occurs—Vascepa does not inhibit platelet aggregation or alter aspirin's COX-1 inhibition meaningfully.[4][5]
Does It Increase Bleeding Risk with Aspirin?
No clinically significant increase. REDUCE-IT reported similar major bleeding rates (2.7% Vascepa vs. 2.9% placebo), even in aspirin users. Per-protocol, patients continued aspirin without dose adjustments.[1][3] Real-world data from EVAPORATE trial (Vascepa plus statins/aspirin) showed plaque regression without excess bleeds.[6]
Guidelines for Heart Patients on Both?
ACC/AHA guidelines endorse Vascepa for eligible high-risk patients on statins, without restricting aspirin co-use. Label advises monitoring bleeding in those on anticoagulants/antiplatelets, but trial data supports safety.[7][1] Prescribers often continue standard secondary prevention aspirin (81 mg).
Who Makes Vascepa and What's the Patent Status?
Amarin Pharmaceuticals manufactures Vascepa. Key U.S. patents (e.g., method-of-use for CV risk reduction) extend protection to 2030, with pediatric exclusivity to 2031. Challenges from generics (e.g., Hikma, Dr. Reddy's) are ongoing via FDA Paragraph IV litigation.[8][9]
Sources
[1]: NEJM - REDUCE-IT Trial
[2]: JAMA Cardiology - REDUCE-IT Aspirin Subgroup
[3]: Amarin REDUCE-IT Analysis
[4]: FDA Vascepa Label
[5]: Clinical Pharmacology Review
[6]: JACC Imaging - EVAPORATE
[7]: AHA/ACC Lipid Guidelines 2018
[8]: DrugPatentWatch - Vascepa Patents
[9]: FDA Orange Book - Vascepa